The Hedgehog inhibitors are promising alternative for patients with advanced 
basal cell carcinoma that are not amenable to radiotherapy or surgery. 
Sonidegib, also known as LDE225, is an orally available SMO antagonist that was 
recently approved by the US FDA for the treatment of patients with locally 
advanced basal cell carcinoma. This article will provide an overview of the 
pharmacology and pharmacokinetics of sonidegib and in-depth analysis of the BOLT 
trial with additional data from the 12-month update. The present challenges 
associated with Hedgehog inhibitors will also be discussed.